Synuclein-One Study

CompletedOBSERVATIONAL
Enrollment

428

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

December 14, 2022

Study Completion Date

November 8, 2023

Conditions
Parkinson DiseaseMultiple System AtrophyDementia With Lewy BodiesPure Autonomic Failure
Interventions
DIAGNOSTIC_TEST

Skin Biopsy

Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.

Trial Locations (23)

10016

NYU Medical Center, New York

11772

SouthShore Neurologic, Patchogue

27710

Duke University Medical Center, Durham

32608

UF College of Medicine, Gainesville

33180

Aventura Neurology, Aventura

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33980

Parkinson's Disease Treatment Center SWFL, Port Charlotte

37232

Vanderbilt University Medical Center, Nashville

55905

Mayo Clinic, Rochester

60201

NorthShore University Health System, Evanston

75390

UTSouthwestern, Dallas

78628

Texas Movement Disorders Specialists, Georgetown

80113

Rocky Mountain Movement Disorders Center, PC, Englewood

85018

CND Life Sciences, Phoenix

85258

Movement Disorders Center of Arizona, Scottsdale

85286

MD First Research, Chandler

90404

Providence St. John's Health, Santa Monica

92011

The Neuro Center, Carlsbad

97225

Providence Brain & Spine Institute, Portland

98034

Evergreen Health, Kirkland

98122

Swedish Neuroscience Research, Seattle

02118

Boston Medical Center, Boston

02215

Beth Israel Lahey Health, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CND Life Sciences

OTHER

NCT04700722 - Synuclein-One Study | Biotech Hunter | Biotech Hunter